Tenon Medical's $15.6M raise clears convertibles and Nasdaq risk, but not the funding question
The SI joint fusion maker used a quarter of financing to repay senior notes early and regain listing compliance. Peers' Q3 raises show how different the small-cap capital market has become.
What happened
Tenon Medical, maker of the SImmetry+ and Catamaran SI joint fusion systems, reported Q3 2026 results on November 12. Revenue rose 22% to $1.4 million, gross margin was 66.3% and net loss was $6.6 million. The financing steps matter as much as the operating numbers. During the quarter Tenon raised about $15.6 million gross, repaid its senior convertible notes early and regained Nasdaq compliance.
The company also began a full commercial launch of a 3D-printed lateral screw for SImmetry+ and added eight U.S. patents. It plans a full market release of the Quickstep Decorticator in Q1 2027.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Tenon Medical Q3 2026 revenue up 22% to $1.4M; convertible notes repaid after $15.6M raised Tenon Medical, Inc. · 12 Nov 2026
- IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M IM Cannabis Corp. · 13 Nov 2026
- Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597 Femasys Inc · 13 Nov 2026
- Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants Mingteng International Corp Inc. · 13 Nov 2026
- Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities Organigram Global Inc. · 13 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Vir's Follow-On Tests Whether Open Equity Windows Favor Platform Stories Over Small-Cap Fixes
Vir Biotechnology's unpriced offering lands the same week as a $225M Windward IPO and a string of warrant-laden small-cap raises, showing how differently capital is available across biotech.
IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics
IM Cannabis's nine-month loss and shareholders' deficit sit against a week of financings in which strategic capital and clinical catalysts, not survival needs, set the terms.
Femasys's $30M placement funds a U.S. launch and a pivotal trial as sales slip 44.5%
Femasys closed a $30M private placement to build a FemaSeed sales team and run the FemBloc pivotal trial. Q3 sales fell 44.5%, and the financing market around it is split between large IPOs and small, structured raises.